CAREERS CONTACT US OUR STORY MEDICINES RESEARCH & DEVELOPMENT IMPACT INVESTORS & MEDIA 1234 Now Approved Our flagship product is now approved by the U.S. FDA for the treatment of patients 12 years and older with locally advanced or metastatic differentiated thyroid cancer that has progressed following prior vascular endothelial growth factor receptor-targeted therapy and who are radioactive iodine-refractory or ineligible. READ MORE Company Statement on COVID-19 Exelixis is actively monitoring the global COVID-19 pandemic, and remains steadfast in our commitment to the health and safety of our patients, customers, employees and local communities. READ MORE 25 Years Resilient Together Learn more about our journey of progress for patients and our efforts to translate drug discovery and development into breakthrough medicines. LEARN MORE Cancer is our Cause We strive to develop effective, tolerable and durable treatments to help patients with cancer thrive. LEARN MORE FEATURED PATIENT STORY ALL VIDEOS Tackling Difficult-to-Treat Cancers To date, we have three medicines available to treat certain types of kidney, liver and thyroid cancers and advanced melanoma. ABOUT OUR MEDICINES Join Us At Exelixis, everyone leads in our collective quest to drive for results so patients can have hope for remission. EXPLORE OPPORTUNITIES FEATURED NEWS ALL NEWS 11/20/2021 Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer at ESMO Asia Virtual Oncology Week 2021 READ MORE 11/09/2021 Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Non-Small Cell Lung Cancer READ MORE 11/03/2021 Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in November and December READ MORE RECENT EVENTS ALL EVENTS 12.01.2021 December 1, 2021 11:45 AM EST : Evercore ISI 4th Annual HealthConX Virtual Conference VIEW EVENT 11.22.2021 November 22, 2021 - November 30, 2021 : Piper Sandler 33rd Annual Virtual Healthcare Conference VIEW EVENT OUR STORY Mission Leadership Board of Directors Collaborations MEDICINES Our Medicines Access RESEARCH & DEVELOPMENT Research & Development Pipeline Clinical Trials IMPACT Why Cancer? Patient Stories Grants & Giving Corporate Responsibility Environmental, Social & Governance Statement on COVID-19 INVESTORS & MEDIA Investors Overview News & Events Stock Information Financial Information Investor Resources Corporate Governance Contact IR © Exelixis, Inc. 2021 Ethics & Compliance Privacy Terms of Use You can learn more from our Privacy Statement. OK